Compare iShares China Large-Cap ETF (FXI) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Eli Lilly And Co — how do they compare? iShares China Large-Cap ETF trades at $33.92 (market cap $3.86B), while Eli Lilly And Co trades at $1,167.63 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 269.4× iShares China Large-Cap ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 149 Days and Eli Lilly And Co for 93 Days on average.
| FXI | LLY | |
|---|---|---|
Market Cap | $3.86B | $1.04T |
Volume | 16,323,837 | 3,064,878 |
52-Week High | $41.08 | $1.28K |
52-Week Low | $31.59 | $799.57 |
Typical Hold Time | 149 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $33.42, down 1.04% with bearish technical signals from moving averages. The ETF faces headwinds from China's economic challenges and trade tensions, though it trades at a significant discount to U.S. equities with a P/E of 11.10 versus the S&P 500's 22.54. Recent geopolitical developments from the Trump-Xi summit and China's export dynamics create mixed sentiment.
The outlook remains cautious with technical indicators signaling selling pressure, while fundamental valuation appears attractive for risk-tolerant investors seeking China exposure. Key risks include ongoing U.S.-China tensions, China's industrial overcapacity, and weak domestic consumption that could limit upside potential despite the valuation discount.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
